retatrutide clinical trial retatrutide VisualAbstract: reduces body weight by 17.5% in patients with obesity Retatrutide UK: 2026 Clinical Trial
Description
This level of demand means benefit managers can no longer treat GLP1 coverage as a niche policy question
AgRP is an antagonist of alpha-MSH at MC3Rs and MC4Rs prevents their activation, whereas GABA inhibits the POMC/CART neurons
Serotonin 2C receptor agonists improve type 2 diabetes via melanocortin-4 receptor signaling pathways
These are often mild and short-lived
A major driver is the sunset of the enhanced premium tax credits, which had held subsidized Marketplace premiums steady in 2024 and 2025
